Abstract:Background. The discovery of the presence of fetal genetic material in maternal blood has opened up a new approach to prenatal diagnosis. One approach that has been extensively investigated over the past few decades is the isolation of fetal cells from maternal blood (Herzenberg et al. Proc Natl Acad Sci USA. 1979;76:1453-5; Bianchi et al. Proc Natl Acad Sci USA. 1990;87:3279-83; Cha et al. Prenat Diagn. 2005-25:586-91). As the fetal cells are scarce and the enrichment is of low efficiency, the technique could not be implemented in clinics. In 1997, Lo et al. (Lancet 1997-350(9076):485-7) discovered that cell-free fetal DNA is present in the plasma and serum of pregnant women. This discovery suggests that maternal plasma/serum DNA may be a useful source of material for non-invasive prenatal diagnosis. The objective of our study was to investigate the feasibility of using fetal DNA in maternal plasma for prenatal diagnosis. Methods. Plasma DNA in 277 blood samples of 40 pregnant women at the gestational period from 5 to 40 weeks and 24 h after delivery were extracted by column separation. FQ-PCR was used to amplify the SRY sequence in 237 plasma samples of 30 pregnant women. Fluorescent PCR was used to amplify 9 short tandem repeat loci simultaneously in 40 plasma samples of 10 pregnant women, and genomic DNA samples from their husbands were amplified by the same method. Results. The fetal SRY sequence could be detected from the 7th week of gestation, with a concentration that increased with progressing gestational age, attaining its highest peak before delivery. Twenty-four hours after delivery, fetal SRY sequence could not be detected in the maternal plasma. The concordance rate of the SRY sequence amplification results of plasma-free DNA, with real fetal gender was 100%. Analysis of maternal plasma samples collected during pregnancy revealed the presence of paternally inherited fetal-specific alleles. Among the 30 collected plasma samples, fetal-specific alleles were detected in 23 plasma DNA samples. The rate of positive results was 76% (23/30), and the frequency of positive results was 6/10 in early pregnancy, 8/10 in middle pregnancy, and 9/10 in late pregnancy. Short tandem repeats could not be detected from the maternal plasma 24 h after delivery. Conclusion. Fluorescent PCR can be used for amplification of fetal SRY sequence and STRs in maternal plasma to obtain fetal genetic information, which may have implications for non-invasive prenatal diagnosis of certain hereditary diseases.

Value of detecting free fDNA in maternal plasma in Down′s syndrome screening

Detection of Cell-Free Fetal DNA in Maternal Serum for a New Prenatal Screening Marker of Down's Syndrome

[Correlation of Free Fetal DNA with Beta-Human Chorionin Gonadotropin in Circulation in Pregnant Women with High Risk of Down's Syndrome].

Detection of Cell-Free Fetal Mrna in Maternal Plasma for a New Prenatal Screening Marker of Down' S Syndrome.

Microarray Detection of Fetal DNA Levels in Maternal Plasma

Study on the relation between ffDNA in maternal plasma and fetal chromosomal eaneuploidy by using QF-PCR

Differentially methylated regions of C21orf25 between maternal and fetal DNA:implication for noninvasive prenatal diagnosis

Screening and Identification of Potential Predictive Biomarkers for Down’s Syndrome from Second Trimester Maternal Serum

Detectionof Fetal Trisomy 8 Mosaicism with Cell-free Fetal DNA in Maternal Plasma

Prenatal Diagnosis of Down Syndrome Using Cell-Free Fetal DNA in Amniotic Fluid by Quantitative Fluorescent Polymersase Chain Reaction.

[Application of Real-Time Fluorescence Quantitative Polymerase Chain Reaction Techniques for Prenatal Diagnosis of Down Syndrome].

Detection of cell-free fetal DNA in maternal plasma using two types of compound markers.

The Urinary Peptidome as a Noninvasive Biomarker Development Strategy for Prenatal Screening of Down's Syndrome.

Detection of Circulating Fetal DNA in Maternal Plasma for Non-Invasive Prenatal Diagnosis

Advent of maternal serum markers for Down syndrome screening

Identification of novel candidate maternal serum protein markers for Down syndrome by integrated proteomic and bioinformatic analysis.

Feasibility Study of Using Fetal DNA in Maternal Plasma for Non‐invasive Prenatal Diagnosis

Quantification of Fetal DNA by Using Methylation-Based Discrimination

Detection of Fetal Dna in Maternal Plasma by Microarray Coupled with Emulsions Pcr

Detection Efficiency of Fetal Epigenetic Marker in Maternal Plasma

Study of Detecting Fetal DNA from Mutual plasma for Prenatal Diagnosis